Sun Pharmaceutical Industries has launched Fexuprazan tablets 40 mg in India under the brand name ‘FEXUCLUE’. FEXUCLUE, a novel potassium competitive acid blocker (PCAB), is approved as a new treatment for adults with Erosive Esophagitis of all grades.
The company has obtained rights from Daewoong Pharmaceutical Co, Korea to manufacture and commercialise FEXUCLUE (Fexuprazan) in India. As per agreement terms, Daewoong will be entitled to upfront and milestone payments, including royalties.
Sun Pharmaceutical Industries is among the largest specialty generic pharmaceutical company and India's top pharmaceutical company.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1851.90 |
| Dr. Reddys Lab | 1273.00 |
| Cipla | 1332.95 |
| Zydus Lifesciences | 933.90 |
| Lupin | 2245.05 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: